author-photo

Michelle DuPont

AstraZeneca

10

Papers

51

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract 4379: Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

2020 Epidemiology
Show All
- Source
- Cite
- Save
Citations (1)
A pharmacokinetic-pharmacodynamic model for the MET-TKI, savolitinib, to explore target inhibition requirements for anti-tumour activity.

2020 British Journal of Pharmacology
Show All
- Source
- Cite
- Save
Citations (0)
Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (16)
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo

2019 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (19)
Abstract 4263: A semi-mechanistic pharmacokinetic-pharmacodynamic (PK-PD) model of savolitinib (AZD6094/HMPL-504), a novel MET inhibitor, to explore extent and duration of target inhibition required for optimal efficacy in the EBC-1 mouse xenograft model

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 39: Discovery of PEN-221, an SSTR2-targeting maytansinoid conjugate with potent activity in vitro and in vivo

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 3674: Pentarins: Improved tumor targeting through nanoparticle encapsulation of miniaturized biologic drug conjugates

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 4484: BTP-114: An albumin binding cisplatin prodrug with improved and sustained tumor growth inhibition

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)